Wall Street analysts forecast that West Pharmaceutical Services (WST) will report quarterly earnings of $2.08 per share in its upcoming release, pointing to a year-over-year increase of 13%. It is anticipated that revenues will amount to $836.8 million, exhibiting an increase of 9.2% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some West Pharmaceutical metrics that are commonly tracked and projected by analysts on Wall Street.
The combined assessment of analysts suggests that 'Net Sales- Contract-Manufactured Products' will likely reach $150.69 million. The estimate points to a change of +2.7% from the year-ago quarter.
Analysts expect 'Net Sales- Proprietary Products' to come in at $688.29 million. The estimate indicates a year-over-year change of +11.1%.
The consensus among analysts is that 'Change in Organic Revenue' will reach 9.3%. Compared to the current estimate, the company reported 6.8% in the same quarter of the previous year.
It is projected by analysts that the 'Gross Profit- Proprietary Products' will reach $279.06 million. The estimate compares to the year-ago value of $248.30 million.
The consensus estimate for 'Gross Profit- Contract-Manufactured Products' stands at $24.97 million. Compared to the present estimate, the company reported $25.60 million in the same quarter last year.
View all Key Company Metrics for West Pharmaceutical here>>>Over the past month, West Pharmaceutical shares have recorded returns of +6.9% versus the Zacks S&P 500 composite's -0.6% change. Based on its Zacks Rank #1 (Strong Buy), WST will likely outperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
West Pharmaceutical Services, Inc. (WST): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).